GIP and GLP-1 Receptor Agonist Tirzepatide Reduces CVD

Click here to subscribe to Diabetesincontrol.com

Categories: Health | Welfare Health Education Age: 14 until 18 year 19 until 30 year 31 until 64 years

3 years ago

Html
Text

Plus: detecting diabetes through waist circumference; more

Saturday, Oct. 09, 2021 : Issue #1169

TOP STORIES - Diabetes News & Research

GIP and GLP-1 Receptor Agonist Tirzepatide Reduces CVD
Empagliflozin Indicated for HFpEF
Waist Circumference and Early Detection of Diabetes
An Update on the Benefits of GLP-1 Receptor Agonists for Type 2 Diabetes
182% Increase of New-Onset T2D in Youth During the COVID-19 Pandemic
Considerations for Making and Achieving Individualized A1c Goals

Letter from the Editor
We keep seeing more evidence on the value of GLP-1 agonists and SGLT-2 inhibitors on protection and improvement in cardio and renal outcomes. This week when Steve and I looked at features from our interns to publish, we selected multiple articles that show how these classes of drugs are making a difference both for diabetes and the comorbidities associated with diabetes.
One of the features shared by Kornelia Ilias, Pharm.D. Candidate, Creighton University School of Pharmacy and Health Professions, adds another class of drugs to the list, and fortunately for us the first in the class also has a GLP-1 agonist effect.
Check out Dr. Ilias’ Laterpay feature to learn what a GIP is, and which new medication has the dual effect.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief

TOP STORIES - Diabetes News and Research

GIP and GLP-1 Receptor Agonist Tirzepatide Reduces CVD
Combo glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.

Empagliflozin Indicated for HFpEF
The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).

Waist Circumference and Early Detection of Diabetes
Measuring waist circumference could provide an inexpensive way to assess risk of developing insulin resistance.

An Update on the Benefits of GLP-1 Receptor Agonists for Type 2 Diabetes
GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.

182% Increase of New-Onset T2D in Youth During the COVID-19 Pandemic
Worse clinical outcomes are seen during the pandemic for non-Hispanic Black youth with T2D.

Considerations for Making and Achieving Individualized A1c Goals
A1c goals are not a one-size-fits-all; here are some factors you might want to think about to help patients meet their target A1c goals.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:

Andy Dao, PharmD Candidate, University of South Florida Taneja College of Pharmacy

Kornelia Ilias, Creighton University | School of Pharmacy and Health Professions Doctor of Pharmacy Candidate Class of 2022

Emmanuella Louissaint, PharmD candidate, LECOM College of Pharmacy

Trina Maglalang RPh, 2022 PharmD Candidate, University of Colorado

Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com

©2021 HIPER, LLC. All rights reserved.
This email was sent by eHealthcare Solutions on behalf of: Diabetes In Control
2093 Philadelphia Pike #8370
Claymont, DE, 19703, United States
DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

GIP and GLP-1 Receptor Agonist Tirzepatide Reduces CVD

Saturday, Oct. 09, 2021 : Issue #1169

TOP STORIES - Diabetes News & Research

TOP STORIES - Diabetes News and Research

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:

Share on

Other newsletters from Diabetesincontrol.com

Related newsletters

View other categories